The Roberts Glore & Co. Inc. IL Acquires New Stake in Allergan PLC (AGN)

The Roberts Glore & Co. Inc. IL Acquires New Stake in Allergan PLC (AGN)

Roberts Glore & Co. Inc. IL acquired a new stake in shares of Allergan PLC (NYSE:AGN) during the second quarter, according to its most recent disclosure with the SEC. The firm acquired 5,132 shares of the company’s stock, valued at approximately $1,186,000.

A number of other hedge funds have also recently made changes to their positions in AGN. Barnett & Company Inc. bought a new position in Allergan PLC during the first quarter valued at approximately $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in Allergan PLC during the second quarter valued at approximately $125,000. Trust Co. of Vermont raised its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Integrated Investment Consultants LLC raised its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Finally, High Point Bank & Trust Co. raised its position in Allergan PLC by 19.9% in the second quarter. High Point Bank & Trust Co. now owns 692 shares of the company’s stock valued at $160,000 after buying an additional 115 shares during the period. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Shares of Allergan PLC (NYSE:AGN) traded down 1.56% during mid-day trading on Monday, hitting $223.99. The company had a trading volume of 3,669,995 shares. Allergan PLC has a one year low of $195.50 and a one year high of $322.68. The firm’s 50-day moving average price is $238.01 and its 200 day moving average price is $238.04. The company has a market capitalization of $88.69 billion, a P/E ratio of 21.33 and a beta of 0.81.

Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. The business earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. Allergan PLC’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted $4.41 earnings per share. Analysts predict that Allergan PLC will post $14.00 earnings per share for the current fiscal year.

AGN has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Allergan PLC in a report on Saturday, June 25th. Bank of America Corp. reaffirmed a “buy” rating and set a $294.00 target price (up from $287.00) on shares of Allergan PLC in a report on Wednesday, June 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Allergan PLC in a report on Wednesday, June 29th. Leerink Swann reaffirmed a “buy” rating on shares of Allergan PLC in a report on Thursday, June 30th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan PLC in a report on Wednesday, July 6th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $302.23.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Related posts

Leave a Comment